Abstract
Nicotinic agonists elicit the release of dopamine from striatal synaptosomes by acting on presynaptic nicotinic acetylcholine receptors (nAChRs) on dopamine nerve terminals. Both α3β2* and α4β2 nAChR subtypes (but not α7* nAChRs) have been implicated. Here, we compared nAChR-evoked [3H]dopamine release from rat striatal synaptosome and slice preparations by using the nicotinic agonist anatoxin-a. In the more integral slice preparation, the concentration-response curve for anatoxin-a-evoked [3H]dopamine release was best fitted to a two-site model, giving EC50 values of 241 nM and 5.1 μM, whereas only the higher-affinity component was observed in synaptosome preparations (EC50 = 134 nM). Responses to a high concentration of anatoxin-a (25 μM) in slices (but not in synaptosomes) were partially blocked by ionotropic glutamate receptor antagonists (kynurenic acid, 6,7-dinitroquinoxaline-2,3-dione) and by α7*-selective nAChR antagonists (α-bungarotoxin, α-conotoxin-ImI, methyllycaconitine) in a nonadditive manner. In contrast, the α3β2-selective nAChR antagonist α-conotoxin-MII partially inhibited [3H]dopamine release from both slice and synaptosome preparations, stimulated with both low (1 μM) and high (25 μM) concentrations of anatoxin-a. Antagonism by α-conotoxin-MII was additive with that of α7*-selective antagonists. These data support a model in which α7* nAChRs on striatal glutamate terminals elicit glutamate release, which in turn acts at ionotropic glutamate receptors on dopamine terminals to stimulate dopamine release. In addition, non-α7* nAChRs on dopamine terminals also stimulate dopamine release. These observations have implications for the complex cholinergic modulation of inputs onto the major efferent neurons of the striatum.
Footnotes
- Received March 13, 2000.
- Accepted May 8, 2000.
-
Send reprint requests to: Dr. S. Wonnacott, Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK. E-mail: s.wonnacott{at}bath.ac.uk
-
↵1 Present address: Department of Biology, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0357.
-
This work was supported by grants from the Biological and Biotechnological Sciences Research Council and European Community.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|